Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

KAPA

Kairos Pharma Ltd

Feb 04 • 04:00PM ET

1.74

Dollar change +0.22
Percentage change 14.47	%

Healthcare • Biotechnology • USA • AMEX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.21	Insider Own	52.20%	Shs Outstand	12.85M	Perf Week	17.57%
Market Cap	22.36M	Forward P/E	-	EPS next Y	-	Insider Trans	0.10%	Shs Float	6.14M	Perf Month	13.73%
Income	-2.74M	PEG	-	EPS next Q	-0.06	Inst Own	3.24%	Short Float	5.62%	Perf Quarter	32.82%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	0.42%	Short Ratio	0.14	Perf Half Y	-
Book/sh	0.26	P/B	6.71	EPS next Y	-	ROA	-92.10%	Short Interest	0.34M	Perf Year	-
Cash/sh	0.25	P/C	6.94	EPS next 5Y	-	ROE	-375.74%	52W Range	0.85 - 4.00	Perf YTD	14.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-82.26%	52W High	-56.50%	Beta	-
Dividend TTM	-	Quick Ratio	2.84	Sales past 5Y	0.00%	Gross Margin	-	52W Low	104.47%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	2.84	EPS Y/Y TTM	-207.94%	Oper. Margin	-	RSI (14)	55.44	Volatility	12.19% 27.20%
Employees	3	Debt/Eq	0.04	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.50
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-235.39%	Payout	-	Rel Volume	4.97	Prev Close	1.52
Sales Surprise	-	EPS Surprise	-150.00%	Sales Q/Q	-	Earnings	Nov 27	Avg Volume	2.54M	Price	1.74
SMA20	14.14%	SMA50	10.94%	SMA200	9.49%	Trades		Volume	11,695,006	Change	14.47%

Jan-28-25 08:15AM	Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024 (Business Wire)
Jan-21-25 08:30AM	Kairos Pharma Provides Business Update and Outlook into 2025 (Business Wire) -8.09%
Jan-07-25 08:15AM	Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit (Business Wire)
Dec-16-24 12:15PM	Kairos Pharma to Participate in The Microcap Conference in January 2025 (ACCESSWIRE)
Dec-03-24 08:30AM	Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial (Business Wire)
08:30AM	Loading…
Nov-19-24 08:30AM	Kairos Pharma Approved to Dual List on Upstream (GlobeNewswire) -14.04%
Oct-22-24 09:00AM	Kairos Pharma to Present at the LD Micro Main Event XVII (GlobeNewswire)
Oct-14-24 06:00AM	Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges (News Direct) +7.80%
Oct-09-24 04:30PM	Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-24-24 04:20PM	Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients (GlobeNewswire) -7.46%
Sep-17-24 04:29PM	Kairos Pharma Closing of $6.2 Million Initial Public Offering (GlobeNewswire) -5.38% -6.50%
Sep-16-24 10:49AM	Kairos Pharma Prices $6.2 Million Initial Public Offering (GlobeNewswire)

Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Murali Ramachandran	VP of Research and Development	Nov 25 '24	Buy	1.59	200	318	133,057	Nov 25 08:30 PM
Samuelson Doug	Chief Financial Officer	Nov 22 '24	Buy	1.50	2,500	3,750	60,796	Nov 25 06:03 AM
Yu John S	CEO and Chairman	Nov 20 '24	Buy	1.44	4,000	5,760	5,341,837	Nov 21 09:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KAPA

Kairos Pharma Ltd

Upgrade your FINVIZ experience